SAM
Simplify Asset Management Portfolio holdings
AUM
$1.65B
This Quarter Return
+4.73%
1 Year Return
+8.73%
3 Year Return
+37.73%
5 Year Return
–
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(+28%)
Cap. Flow
+$261M
Cap. Flow
% of AUM
17.92%
Top 10 Holdings %
Top 10 Hldgs %
74.27%
Holding
127
New
16
Increased
47
Reduced
20
Closed
15
Top Buys
Top Sells
| 1 |
Simplify High Yield ETF
CDX
|
$63.4M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
$28.6M |
| 3 |
Merck
MRK
|
$6.35M |
| 4 |
Boston Scientific
BSX
|
$6.13M |
| 5 |
Novo Nordisk
NVO
|
$5.63M |
Sector Composition
| 1 | Healthcare | 18.32% |
| 2 | Energy | 1.62% |
| 3 | Industrials | 1.53% |
| 4 | Technology | 0.5% |
| 5 | Real Estate | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Akero Therapeutics
AKRO
$3.74B
| $8.14M | 0.38% |
283,766
+38,279
| +16% | +$1.1M |
|
27
Gilead Sciences
GILD
$140B
| $8.07M | 0.38% |
+96,202
| New | +$8.07M |
|
28
Cigna
CI
$80.3B
| $7.25M | 0.34% |
20,933
+16,045
| +328% | +$5.56M |
|
29
Avidity Biosciences
RNA
$5.99B
| $5.74M | 0.27% |
125,000
| – | – |
|
30
3M
MMM
$82.8B
| $5.39M | 0.25% |
39,434
+4,583
| +13% | +$626K |
|
31
Chewy
CHWY
$16.9B
| $5.38M | 0.25% |
+183,662
| New | +$5.38M |
|
32
TScan Therapeutics
TCRX
$102M
| $5.21M | 0.24% |
1,046,916
| – | – |
|
33
Madrigal Pharmaceuticals
MDGL
$9.76B
| $4.95M | 0.23% |
23,305
-8
| -0% | -$1.7K |
|
34
Tandem Diabetes Care
TNDM
$845M
| $4.86M | 0.23% |
+114,604
| New | +$4.86M |
|
35
Telesat
TSAT
$307M
| $4.82M | 0.22% |
365,781
| – | – |
|
36
Teleflex
TFX
$5.59B
| $4.8M | 0.22% |
+19,408
| New | +$4.8M |
|
37
Myriad Genetics
MYGN
$593M
| $4.76M | 0.22% |
+173,626
| New | +$4.76M |
|
38
Ardelyx
ARDX
$1.53B
| $4.75M | 0.22% |
689,364
+91,364
| +15% | +$629K |
|
39
Elevance Health
ELV
$71.8B
| $4.56M | 0.21% |
8,762
+3,526
| +67% | +$1.83M |
|
40
Simplify Short Term Treasury Futures Strategy ETF
TUA
$641M
| $3.81M | 0.18% |
165,526
+64,042
| +63% | +$1.47M |
|
41
Revvity
RVTY
$10.5B
| $3.1M | 0.14% |
24,303
-1,469
| -6% | -$188K |
|
42
Leap Therapeutics
LPTX
$12M
| $2.72M | 0.13% |
1,056,895
+425,626
| +67% | +$1.09M |
|
43
Royalty Pharma
RPRX
$15.6B
| $2.66M | 0.12% |
94,066
+37,878
| +67% | +$1.07M |
|
44
Abeona Therapeutics
ABEO
$350M
| $2.58M | 0.12% |
408,584
| – | – |
|
45
Annaly Capital Management
NLY
$13.6B
| $2.47M | 0.12% |
123,302
+30,102
| +32% | +$604K |
|
46
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.35M | 0.11% |
122,185
+46,992
| +62% | +$905K |
|
47
IQVIA
IQV
$32.4B
| $2.28M | 0.11% |
9,637
+3,894
| +68% | +$923K |
|
|
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.26M | 0.11% |
30,883
+12,346
| +67% | +$903K |
|
49
Avantor
AVTR
$9.18B
| $2.19M | 0.1% |
84,678
+34,102
| +67% | +$882K |
|
|
EQLS
50
DELISTED
Simplify Market Neutral Equity Long/Short ETF
EQLS
| $2.05M | 0.1% |
94,670
-27,052
| -22% | -$585K |
|